Skip to content

PTC Therapeutics PTCT Current maturities of long-term debt

Current maturities of long-term debt at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Moderna logo
ModernaMRNA
Insmed logo
InsmedINSM

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$6.55B+40.3%
Enterprise value$6.11B+77.3%
P/E
P/S7.9×+5.3×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.

The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's current maturities of long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTC Therapeutics's current maturities of long-term debt?
PTC Therapeutics (PTCT) reported current maturities of long-term debt of $6M in Q1 2026.
How has PTC Therapeutics's current maturities of long-term debt changed year-over-year?
PTC Therapeutics's current maturities of long-term debt increased by 18.9% year-over-year, from $5.05M to $6M.
What is the long-term trend for PTC Therapeutics's current maturities of long-term debt?
Over 5 years (2020 to 2025), PTC Therapeutics's current maturities of long-term debt has grown at a 18.6% compound annual growth rate (CAGR), from $1.28M to $3M.